[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"painful-diabetic-peripheral-neuropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:painful-diabetic-peripheral-neuropathy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100653258","efficacy-and-safety-of-low-dose-duloxetine-plus-alpha-lipoic-acid-versus-standard-dose-duloxetine-in-painful-diabetic-peripheral-neuropathy-100653258",false,"NCT07785544","Efficacy and Safety of Low-Dose Duloxetine Plus Alpha-Lipoic Acid Versus Standard-Dose Duloxetine in Painful Diabetic Peripheral Neuropathy","Efficacy and Safety of Low-Dose Duloxetine Plus Alpha-Lipoic Acid Versus Standard-Dose Duloxetine in Painful Diabetic Peripheral Neuropathy: An Assessor-Blinded Randomized Controlled Non-Inferiority Trial","Inclusion Criteria:\n\n* Age ≥18 years.\n* Diagnosed case of diabetes mellitus.\n* Diabetic peripheral neuropathy diagnosed clinically according to the Toronto Clinical Neuropathy Score (TCNS) criteria with a TCNS score ≥6, with painful neuropathy confirmed using the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) Pain Scale with a score ≥12.\n* Duration of neuropathic symptoms ≥3 months.\n* Baseline Numerical Rating Scale (NRS) pain score ≥4.\n* Willingness to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Pain attributable to causes other than diabetic peripheral neuropathy, such as peripheral arterial disease (ischaemic pain), osteoarthritis, inflammatory arthritis, phantom limb pain, radiculopathy, or other chronic pain disorders.\n* Known vitamin B12 deficiency, hypothyroidism, chronic alcohol use, hereditary neuropathy, chemotherapy-induced neuropathy, HIV infection, or connective tissue disease.\n* Chronic kidney disease (CKD) stage ≥4.\n* Chronic liver disease or significant hepatic impairment (ALT \\>3 times the upper normal limit).\n* Use of antidepressants, antiepileptic drugs, sedatives, antipsychotic drugs, or opioids within the preceding 4 weeks.\n* Pregnancy or lactation, or women planning pregnancy during the study period.\n* Known hypersensitivity or contraindication to duloxetine or alpha-lipoic acid.\n* Major depressive disorder as assessed by the Patient Health Questionnaire-9 (PHQ-9), cognitive impairment (MMSE \\\u003C24), active malignancy, or any serious medical condition that, in the opinion of the investigator, may interfere with study participation, treatment adherence, or outcome assessment.","ALL","18 Years",{"count":19,"type":20},170,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study will evaluate the efficacy and safety of low-dose duloxetine combined with alpha-lipoic acid compared with standard-dose duloxetine in adults with painful diabetic peripheral neuropathy. In this assessor-blinded, randomized, parallel-arm, non-inferiority trial, participants will be assigned in a 1:1 ratio to receive either duloxetine 30 mg once daily plus alpha-lipoic acid 600 mg once daily or duloxetine 60 mg once daily. The primary outcome will be the change in pain intensity measured by the Numerical Rating Scale from baseline to Week 9. Secondary outcomes will include changes in pain intensity at Week 5, Patient Global Impression of Change at Weeks 5 and 9, the proportion of participants achieving at least a 30% reduction in pain intensity, adverse effects, treatment tolerability and treatment compliance.",[26],"Painful Diabetic Peripheral Neuropathy","NOT_YET_RECRUITING","2026-08-21",{"date":30,"type":31},"2026-08-25","ACTUAL",{"date":30,"type":20},{"date":34,"type":20},"2027-08",{"name":36,"class":37},"Bangladesh Medical University","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":52,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":38},"100649926","the-effects-of-ceylon-cinnamon-cinnamomum-verum-supplementation-on-blood-glucose-lipid-profile-levels-body-mass-index-and-pain-intensity-among-adult-individuals-with-painful-diabetic-peripheral-neuropathy-100649926","NCT07743073","The Effects of Ceylon Cinnamon (Cinnamomum Verum) Supplementation on Blood Glucose, Lipid Profile Levels, Body Mass Index, and Pain Intensity Among Adult Individuals With Painful Diabetic Peripheral Neuropathy","The Effects of Ceylon Cinnamon (Cinnamomum Verum) Supplementation on Blood Glucose, Lipid Profile Levels, Body Mass Index, and Pain Intensity Among Adult Individuals With Painful Diabetic Peripheral Neuropathy: A Double-Blind Randomized Controlled Trial","PDPN- CC-RCT","Inclusion Criteria:\n\n* Age ≥ 18years diagnosed with PDPN\n* With documented T2DM\n\nExclusion Criteria:\n\n* If they had coexisting chronic conditions, including chronic kidney disease (CKD), hypertension, cardiovascular disease (CVD), or cognitive\u002Fsensory impairments (e.g., reading or hearing difficulties).\n* individuals receiving medications that could confound blood glucose control or pain perception (such as systemic glucocorticoids, weight-loss agents, or iron and vitamin B12 supplements)",{"count":48,"type":20},164,[23],"Background: Painful diabetic peripheral neuropathy (PDPN) is a severe, disabling complication of type 2 diabetes mellitus (T2DM), closely associated with insulin resistance, chronic neuroinflammation, and oxidative stress. Plant-based dietary supplements, particularly Ceylon cinnamon (Cinnamomum verum), contain bioactive compounds with potential anti-diabetic, antioxidant, and neuroprotective properties.\n\nAim: To evaluate the effects of Ceylon Cinnamon (Cinnamomum verum) supplementation on blood glucose, lipid profile levels, body mass index (BMI), and pain intensity among adult individuals with painful diabetic peripheral neuropathy (PDPN).\n\nMethods: A prospective, double-blind, randomized controlled trial (Double-Blind RCT) was conducted (Feb-July 2026) across endocrinology outpatient clinics in Jordan. Participants were randomly allocated in a 1:1 ratio to either the Intervention Group (n = 62; 500 mg Ceylon cinnamon twice daily for 6 months alongside standard care) or the Placebo Control Group (n = 62; 500 mg placebo capsules twice daily for 6 months alongside standard care). Clinical, biochemical, and pain assessments (using the Numeric Rating Scale \\[NRS\\]) were evaluated at baseline, 3 months, and 6 months post-intervention.",[26],[53,54,55,56],"Painful diabetic peripheral neuropathy","Ceylon cinnamon (Cinnamomum verum)","Insulin resistance","Neuropathic pain","RECRUITING","2026-07-29",{"date":60,"type":31},"2026-08-03",{"date":62,"type":31},"2026-02-01",{"date":64,"type":20},"2026-07-30",{"name":66,"class":37},"JAWAD AHMAD ABU-SHENNAR",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":77,"conditions":78,"keywords":79,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":38},"100528266","high-frequency-scs-versus-scs-in-the-treatment-of-diabetic-peripheral-neuropathic-pain-100528266","NCT06158529","High-frequency SCS Versus SCS in the Treatment of Diabetic Peripheral Neuropathic Pain","A Multicentre Clinical Study of High-frequency Electrical Spinal Cord Stimulation Versus Electrical Spinal Cord Stimulation in the Treatment of Diabetic Peripheral Neuropathic Pain","Inclusion Criteria:\n\n1. Diagnosed with diabetes, aged between 18 and 80 years old;\n2. Symmetrical pain in the distal lower extremities with or without dysesthesia;\n3. Duration of symptoms exceeding 6 months;\n4. Pain described as stabbing and\u002For electric shock-like and\u002For burning sensation;\n5. Abnormal Quantitative Sensory Testing (QST);\n6. Presence of hyperalgesia and allodynia;\n7. Absence of lower limb reflexes and muscle strength abnormalities;\n8. Normal MRI or CT scans without spinal canal stenosis or other spinal abnormalities.\n\nExclusion Criteria:\n\n1. Concurrent severe cardiovascular and cerebrovascular diseases;\n2. History of lumbar spine surgery, trauma, or spinal canal stenosis within the past 6 months, or a history of lumbar spine surgery, trauma, or spinal canal stenosis that would impact the SCS surgery and pain assessment in this study;\n3. Presence of radicular symptoms;\n4. Other spinal abnormalities, such as benign or malignant tumors, congenital abnormalities of the spine, spinal instability, etc.;\n5. Coexisting disorders of the coagulation system, malignant tumors, infections, and psychiatric or psychological disorders;\n6. Pregnancy.","80 Years",{"count":38,"type":20},[23],"Application of High-Frequency Spinal Cord Stimulation (HF-SCS) in the Treatment of Painful Diabetic Peripheral Neuropathy (PDPN): A multicenter, randomized controlled study comparing its clinical efficacy with traditional spinal cord stimulation for PDPN. The study aims to observe the impact of HF-SCS on the neurological function and microcirculation of PDPN patients, elucidating the correlation between the underlying diabetes and the efficacy of HF-SCS therapy on PDPN. The goal is to enhance the treatment standards for PDPN, improve the quality of life for this population, and overall treatment outcomes. Simultaneously, the study aims to contribute evidence-based medicine for the mechanistic exploration of PDPN.",[26],[80],"spinal cord stimulation","2025-02-23",{"date":83,"type":31},"2025-02-25",{"date":85,"type":31},"2025-01-06",{"date":87,"type":20},"2025-12-31",{"name":89,"class":37},"Fan BiFa"]